Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $17.6600 (3.91%) ($16.8900 - $17.8400) on Wed. Oct. 21, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.81% (three month average) | RSI | 82 | Latest Price | $17.6600(3.91%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 1.5% a day on average for past five trading days. | Weekly Trend | FOLD advances 9.7% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(53%) IWO(50%) XBI(49%) IWM(46%) IWC(44%) | Factors Impacting FOLD price | FOLD will decline at least -1.405% in a week (0% probabilities). VIXM(-28%) VXX(-14%) UUP(-11%) UNG(-5%) DRIV(-3%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.405% (StdDev 2.81%) | Hourly BBV | 2 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | 5 Day Moving Average | $17.12(3.15%) | 10 Day Moving Average | $16.46(7.29%) | 20 Day Moving Average | $15.33(15.2%) | To recent high | 0% | To recent low | 37.2% | Market Cap | $4.56b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |